N17 Exploration of medication non-adherence in Inflammatory Bowel Disease patients: A systematic review

K. King, C. Norton, T. Chalder, W. Czuber-dochan
{"title":"N17 Exploration of medication non-adherence in Inflammatory Bowel Disease patients: A systematic review","authors":"K. King, C. Norton, T. Chalder, W. Czuber-dochan","doi":"10.1093/ecco-jcc/jjad212.1389","DOIUrl":null,"url":null,"abstract":"\n \n \n Inflammatory bowel disease (IBD) has recognised medications to maintain remission and prevent relapse. Yet between 53–75% of people with IBD do not take medications as prescribed. Identifying and improving medication adherence in IBD is a primary treatment goal to keep symptoms quiescent.\n This systematic review aims to identify why people are adherent and non-adherent to IBD medications.\n \n \n \n Studies exploring medication adherence for IBD conducted between 2012-2022, were identified in six electronic databases.\n The quality of quantitative and qualitative studies was assessed using a scoring system or the Critical Appraisal Skills Programme, respectively.\n \n \n \n 39,603 participants were included across 79 studies investigating IBD medication adherence, mainly from single outpatient clinic populations, using cross-sectional surveys.\n Most data were quantitative, rated medium quality. Few studies were based around a theory to explain adherence.\n Non-adherence was most typically measured using a version of the Morisky Medication Adherence Scale or the study’s own self-report questionnaire, with non-adherence ranging from 4.3%-88.9%.\n In multivariable analysis of quantitative data, younger age and female gender were usually associated with non-adherence. The presence of smoking, psychological issues (depression, treatment concerns, anxiety) or lower social status were also significant non-adherence risk factors. Most typically investigated were clinical variables, many being significantly related with non-adherence, including medication type (specifically 5-ASA), route (oral, rectal, subcutaneous, intravenous), high and low disease activity and poor disease/medication knowledge. Significant results were often contradictory between studies, as was the relationship direction with non-adherence.\n Forgetting medication was the main reason for non-adherence in qualitative interviews, with side effects, costs, medication concerns and busy lifestyle also variables.\n Cohort-specific factors were reported for non-adherence in pregnant women, adolescents and patients during COVID.Conclusion\n Adherence to treatment is essential in IBD. Yet a large and confusing literature exists regarding factors underpinning non-adherence.\n Clinicians should be aware of those non-modifiable factors, to help identify relevant patients and support their treatment programme.\n Potentially modifiable factors including medication regimes, route and patient knowledge, could be targeted to improve adherence in IBD.\n Theoretically informed interventions need to be developed. A successful evidence-based intervention supporting medication adherence could help improve quality of life for patients living with IBD, whilst providing patient-centred care and minimising health costs.\n","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"38 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohn's and Colitis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjad212.1389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease (IBD) has recognised medications to maintain remission and prevent relapse. Yet between 53–75% of people with IBD do not take medications as prescribed. Identifying and improving medication adherence in IBD is a primary treatment goal to keep symptoms quiescent. This systematic review aims to identify why people are adherent and non-adherent to IBD medications. Studies exploring medication adherence for IBD conducted between 2012-2022, were identified in six electronic databases. The quality of quantitative and qualitative studies was assessed using a scoring system or the Critical Appraisal Skills Programme, respectively. 39,603 participants were included across 79 studies investigating IBD medication adherence, mainly from single outpatient clinic populations, using cross-sectional surveys. Most data were quantitative, rated medium quality. Few studies were based around a theory to explain adherence. Non-adherence was most typically measured using a version of the Morisky Medication Adherence Scale or the study’s own self-report questionnaire, with non-adherence ranging from 4.3%-88.9%. In multivariable analysis of quantitative data, younger age and female gender were usually associated with non-adherence. The presence of smoking, psychological issues (depression, treatment concerns, anxiety) or lower social status were also significant non-adherence risk factors. Most typically investigated were clinical variables, many being significantly related with non-adherence, including medication type (specifically 5-ASA), route (oral, rectal, subcutaneous, intravenous), high and low disease activity and poor disease/medication knowledge. Significant results were often contradictory between studies, as was the relationship direction with non-adherence. Forgetting medication was the main reason for non-adherence in qualitative interviews, with side effects, costs, medication concerns and busy lifestyle also variables. Cohort-specific factors were reported for non-adherence in pregnant women, adolescents and patients during COVID.Conclusion Adherence to treatment is essential in IBD. Yet a large and confusing literature exists regarding factors underpinning non-adherence. Clinicians should be aware of those non-modifiable factors, to help identify relevant patients and support their treatment programme. Potentially modifiable factors including medication regimes, route and patient knowledge, could be targeted to improve adherence in IBD. Theoretically informed interventions need to be developed. A successful evidence-based intervention supporting medication adherence could help improve quality of life for patients living with IBD, whilst providing patient-centred care and minimising health costs.
N17 探讨炎症性肠病患者不遵医嘱用药的情况:系统回顾
炎症性肠病(IBD)有公认的药物来维持缓解和预防复发。然而,53%-75% 的 IBD 患者并没有遵医嘱服药。确定并改善 IBD 患者的服药依从性是保持症状稳定的首要治疗目标。本系统综述旨在确定 IBD 患者坚持或不坚持服药的原因。 我们在六个电子数据库中找到了 2012-2022 年间进行的探讨 IBD 药物依从性的研究。定量和定性研究的质量分别采用评分系统或批判性评估技能计划进行评估。 79项研究共纳入了39,603名参与者,这些研究采用横断面调查的方式调查了IBD患者的用药依从性,这些患者主要来自单个门诊诊所人群。大部分数据为定量数据,质量中等。很少有研究基于某种理论来解释服药依从性。不依从性最典型的测量方法是莫里斯基用药依从性量表或研究者自己的自我报告问卷,不依从性从4.3%-88.9%不等。在对定量数据进行多变量分析时,年轻和女性通常与不依从性有关。吸烟、心理问题(抑郁、对治疗的担忧、焦虑)或社会地位较低也是不坚持治疗的重要风险因素。最典型的调查对象是临床变量,其中许多变量与不依从性显著相关,包括药物类型(特别是 5-ASA)、途径(口服、直肠、皮下、静脉注射)、疾病活动性高低以及疾病/用药知识贫乏。不同研究之间的重要结果往往相互矛盾,与不依从性的关系方向也是如此。在定性访谈中,忘带药物是不坚持用药的主要原因,副作用、费用、用药顾虑和繁忙的生活方式也是可变因素。据报道,孕妇、青少年和 COVID 期间的患者不坚持用药的特定因素。结论 坚持治疗对 IBD 患者至关重要,但关于不坚持治疗的因素,存在大量令人困惑的文献。临床医生应了解这些不可改变的因素,以帮助识别相关患者并支持他们的治疗方案。可以针对潜在的可改变因素(包括用药方案、途径和患者知识)来改善 IBD 患者的依从性。需要制定有理论依据的干预措施。支持坚持用药的成功循证干预措施有助于提高 IBD 患者的生活质量,同时提供以患者为中心的护理并最大限度地降低医疗成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信